---
title: "DRMA.US (DRMA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DRMA.US/news.md"
symbol: "DRMA.US"
name: "DRMA.US"
parent: "https://longbridge.com/en/quote/DRMA.US.md"
datetime: "2026-05-20T09:05:18.907Z"
locales:
  - [en](https://longbridge.com/en/quote/DRMA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DRMA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DRMA.US/news.md)
---

# DRMA.US (DRMA.US) — Related News

### [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
*2026-05-19T19:45:38.000Z*
> Analyst Anthony Vendetti from Maxim Group has reiterated a Buy rating on Dermata Therapeutics, maintaining a 12-month pr

### [Dermata Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286311064.md)
*2026-05-13T20:17:49.000Z*
### [Dermata Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286309961.md)
*2026-05-13T20:10:51.000Z*
### [Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements](https://longbridge.com/en/news/285052237.md)
*2026-05-04T09:37:33.000Z*
> Dermapharm Holding SE has announced the upcoming publication of its quarterly financial report for Q1 of the 1st half-ye

### [Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News](https://longbridge.com/en/news/284680691.md)
*2026-04-29T18:35:37.000Z*
> Veradermics Announces Pricing of Upsized Public Offering and Private Placement | MANE Stock News

### [Galderma Posts Q1 Sales Growth, Confirms FY26 Outlook, Stock Up](https://longbridge.com/en/news/283794525.md)
*2026-04-23T08:50:46.000Z*
> Galderma Group AG reported a 30.5% increase in Q1 net sales to $1.47 billion, driven by strong performance across all se

### [Global Keloid Treatment Market Outlook | North America, Asia Pacific, Europe Lead | Bausch Health, Sciton, Galderma Drive Multi-Modal Dermatology Innovation](https://longbridge.com/en/news/282167578.md)
*2026-04-09T09:30:27.000Z*
> The global keloid treatment market is evolving into a clinically driven segment, projected to grow from USD 4.29 billion

### [Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause](https://longbridge.com/en/news/282137185.md)
*2026-04-09T05:16:05.000Z*
> Interim data from two investigator-initiated trials (IITs) supported by Galderma highlight the effectiveness of Sculptra

### [A transaction that made a profit of 182.3 billion in 7 years](https://longbridge.com/en/news/281704989.md)
*2026-04-05T08:03:10.000Z*
> EQT (EQT Group) set a record for its largest exit in history through the final divestment of the global dermatology comp

### [Dermata Therapeutics | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/280690141.md)
*2026-03-26T21:20:11.000Z*